Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014.

Company profile
Ticker
TECH
Exchange
Website
CEO
Charles Kummeth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Denali Therapeutics • Allogene Therapeutics ...
Former names
TECHNE CORP /MN/
SEC CIK
Corporate docs
Subsidiaries
Research and Diagnostic Systems Inc. • Bionostics, Inc • Bio-Techne China Co. Ltd • Shanghai PrimeGene Bio-Tech Co., Ltd. • ProteinSimple Ltd. • Novus Biologicals, LLC • Bio-Techne Ltd. • Tocris Cookson Limited • Cliniqa Corporation • Advanced Cell Diagnostics, Inc. ...
IRS number
411427402
TECH stock data
News
Bio-Techne To Acquire Namocell; Terms Not Disclosed
22 Jun 22
Stocks That Hit 52-Week Lows On Tuesday
14 Jun 22
Bio-Techne Announced Milerson 40,000 Unique RNAscope in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species
26 May 22
Bio-Techne Reports Exclusive Supply Deal With Nonagen Bioscience For Nonagen's Oncuria Bladder Cancer Test, No Terms Disclosed
12 May 22
Keybanc Maintains Overweight on Bio-Techne, Lowers Price Target to $500
5 May 22
Press releases
BIO-TECHNE TO ACQUIRE NAMOCELL
22 Jun 22
Tackling Recurring Health Conditions Offers Hope to Patients
21 Jun 22
Bio-Techne Celebrates 40,000 Unique RNAscope™ in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species.
26 May 22
GLOBAL STUDY DEMONSTRATES ICE3 AND MAURICE CAPILLARY ISOELECTRIC FOCUSING COMPARABILITY IN THE JOURNAL OF ELECTROPHERESIS
25 May 22
BIO-TECHNE TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE
19 May 22
Analyst ratings and price targets
Current price
Average target
$435.00
Low target
$370.00
High target
$500.00
Keybanc
Maintains
$500.00
Wells Fargo
Downgraded
$370.00
Calendar
9 May 22
26 Jun 22
30 Jun 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 21 | Jun 20 | Jun 19 | Jun 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 160.82M | 160.82M | 160.82M | 160.82M | 160.82M | 160.82M |
Cash burn (monthly) | 17.01M | 2.11M | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 48.81M | 6.05M | n/a | n/a | n/a | n/a |
Cash remaining | 112.01M | 154.77M | n/a | n/a | n/a | n/a |
Runway (months of cash) | 6.6 | 73.4 | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Jun 22 | Higgins John L | Common Stock | Sell | Dispose S | No | No | 366.09 | 600 | 219.65K | 4,606 |
8 Jun 22 | Higgins John L | Common Stock | Option exercise | Acquire M | No | No | 66.9 | 600 | 40.14K | 5,206 |
8 Jun 22 | Higgins John L | Stock Options Common Stock | Option exercise | Dispose M | No | No | 66.9 | 600 | 40.14K | 3,400 |
7 Jun 22 | Kummeth Charles R. | Common Stock | Sell | Dispose S | No | No | 365 | 5,104 | 1.86M | 198,338 |
7 Jun 22 | Kummeth Charles R. | Common Stock | Option exercise | Acquire M | No | No | 108.49 | 5,104 | 553.73K | 203,442 |
7 Jun 22 | Kummeth Charles R. | Stock Option Common Stock | Option exercise | Dispose M | No | No | 108.49 | 5,104 | 553.73K | 95,346 |
7 Jun 22 | Higgins John L | Common Stock | Sell | Dispose S | No | No | 364.31 | 1,000 | 364.31K | 4,606 |
7 Jun 22 | Higgins John L | Common Stock | Option exercise | Acquire M | No | No | 66.9 | 1,000 | 66.9K | 5,606 |
7 Jun 22 | Higgins John L | Stock Options Common Stock | Option exercise | Dispose M | No | No | 66.9 | 1,000 | 66.9K | 4,000 |
10 May 22 | Baumgartner Robert V | Common Stock | Buy | Acquire P | No | No | 352.55 | 300 | 105.77K | 10,106 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
attack, bond, breach, cyber, cybersecurity, electronic, exclusive, ExoTRU, hematology, hold, kidney, network, patching, processing, recast, rejection, storing, system, training, transmission, transplant, unfavorable, unknown, vulnerable
Removed:
finalize, science
Financial reports
Current reports
8-K
Bio-techne Releases Third Quarter Fiscal 2022 Results
4 May 22
8-K
Amendments to Articles of Incorporation or Bylaws
27 Apr 22
8-K
Bio-techne Releases Second Quarter Fiscal 2022 Results
1 Feb 22
8-K
Bio-techne Announces Appointment of Will Geist As President, Protein Sciences Segment
22 Dec 21
8-K
Bio-techne Releases First Quarter Fiscal 2022 Results
2 Nov 21
8-K
Submission of Matters to a Vote of Security Holders
29 Oct 21
8-K
Bio-techne Releases Fourth Quarter Fiscal 2021 Results
5 Aug 21
8-K
Bio-techne Releases Third Quarter Fiscal 2021 Results
6 May 21
8-K
Bio-techne Releases Second Quarter Fiscal 2021 Results
2 Feb 21
8-K
Bio-techne Releases First Quarter Fiscal 2021 Results
5 Nov 20
Registration and prospectus
S-8
Registration of securities for employees
9 Nov 20
S-8
Registration of securities for employees
7 Nov 18
S-8
Registration of securities for employees
25 Oct 17
S-8
Registration of securities for employees
29 Oct 15
S-8
Registration of securities for employees
3 Nov 14
S-8
Registration of securities for employees
11 Nov 10
S-8
Registration of securities for employees
14 Nov 00
S-8
Registration of securities for employees
12 Oct 99
S-3
Shelf registration
30 Sep 98
S-8
Registration of securities for employees
5 Oct 97
Proxies
DEFA14A
Additional proxy soliciting materials
15 Sep 21
DEFA14A
Additional proxy soliciting materials
15 Sep 20
DEFA14A
Additional proxy soliciting materials
9 Sep 19
DEFA14A
Additional proxy soliciting materials
10 Sep 18
DEF 14A
Definitive proxy
11 Sep 17
DEFA14A
Additional proxy soliciting materials
11 Sep 17
Other
SD
Conflict minerals disclosure
31 May 22
SD
Conflict minerals disclosure
28 May 21
UPLOAD
Letter from SEC
15 Apr 21
CORRESP
Correspondence with SEC
28 Mar 21
UPLOAD
Letter from SEC
16 Mar 21
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
29 May 19
SD
Conflict minerals disclosure
25 May 18
UPLOAD
Letter from SEC
30 Apr 18
CORRESP
Correspondence with SEC
4 Apr 18
Ownership
4
BIO-TECHNE / JOHN L HIGGINS ownership change
9 Jun 22
4
BIO-TECHNE / Charles R. Kummeth ownership change
9 Jun 22
4
BIO-TECHNE / ROBERT V BAUMGARTNER ownership change
11 May 22
4
BIO-TECHNE / Kim Kelderman ownership change
10 Feb 22
SC 13G/A
BIO-TECHNE / VANGUARD ownership change
9 Feb 22
3
BIO-TECHNE / William Geist ownership change
3 Feb 22
4
BIO-TECHNE / William Geist ownership change
3 Feb 22
4
BIO-TECHNE / Charles R. Kummeth ownership change
1 Feb 22
SC 13G/A
BIO-TECHNE / BlackRock ownership change
27 Jan 22
SC 13G/A
BIO-TECHNE / BlackRock ownership change
25 Jan 22
Patents
Utility
Detection of Double Stranded Nucleic Acids In Situ and Methods Related Thereto
9 Jun 22
The invention provides methods for detecting target double stranded nucleic acids, including for in situ hybridization assays.
Utility
Surface Plasmon Resonance Sensor Chip Having Sensor Surface Capable of Capturing Multiple Species of Antibodies and Method of Making
2 Jun 22
A surface plasmon resonance chip includes a sensor surface having a substrate, an inert metal layer directly on the substrate, a surface layer directly on the inert metal layer, and fusion proteins immobilized on the surface layer.
Utility
Methods for Digital Multiplexing of Nucleic Acids In Situ
21 Apr 22
The invention relates to methods of multiplex detection of a plurality of target nucleic acids using combinations of labels by contacting a sample comprising a cell comprising a plurality of target nucleic acids with a set of probes, wherein the set of probes comprises subsets of probes comprising a plurality detectable labels that provide unique labeling of each target nucleic acid, wherein each probe subset comprises one or more distinct labels, wherein the number and/or combination of distinct labels is unique for each target nucleic acid; and detecting the detectable labels bound to the respective target nucleic acids.
Utility
In Situ Detection of Nucleotide Variants In High Noise Samples, and Compositions and Methods Related Thereto
23 Dec 21
The invention relates to methods of in situ detection of a nucleic acid variation of a target nucleic acid in a sample, including single nucleotide variations, multi-nucleotide variations or splice sites.
Utility
WNT/SFRP Complexes, Wnt-containing Compositions, Wnt-expressing Cells, and Methods of Making, Purifying, and Using Same
9 Dec 21
This disclosure describes isolated protein complexes including a Wnt and a sFRP; compositions including a Wnt; a cell overexpressing a Wnt and a sFRP; compositions including a cell overexpressing a Wnt and a cell overexpressing a sFRP; methods of making the protein complexes, compositions, and cells; and methods of using the isolated protein complexes, compositions, and cells.
Transcripts
2022 Q3
Earnings call transcript
4 May 22
2022 Q2
Earnings call transcript
1 Feb 22
2022 Q1
Earnings call transcript
2 Nov 21
2021 Q4
Earnings call transcript
7 Aug 21
2021 Q3
Earnings call transcript
9 May 21
2021 Q2
Earnings call transcript
2 Feb 21
2021 Q1
Earnings call transcript
8 Nov 20
2020 Q4
Earnings call transcript
4 Aug 20
2020 Q3
Earnings call transcript
1 May 20
2020 Q2
Earnings call transcript
4 Feb 20
Reddit threads
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22
BITCOIN is going to ZERO !! Every WARREN BUFFETT WARNING about CRYPTO. Compilation
18 Jun 22
Give me a company and I will make a Discounted Cash Flow (DCF) model.
7 Jun 22
Stocks with rising net income the last few quarters?
24 May 22
Daily Plays May 24, 2022
24 May 22
Daily Plays May 23, 2022
23 May 22
Daily Plays May 22, 2022
22 May 22
Daily Plays May 21, 2022
21 May 22
$SNPW COMMITTED TO BUILD 1GW SOLAR PANEL MANUFACTURING FACTORY
20 May 22
TECH Tesla whale calls for $15 billion stock buyback after share price craters
19 May 22